Zeke Capital Advisors LLC boosted its stake in shares of Eli Lilly and Co (NYSE:LLY) by 7.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 25,661 shares of the company’s stock after buying an additional 1,815 shares during the period. Zeke Capital Advisors LLC’s holdings in Eli Lilly and were worth $2,167,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Gradient Investments LLC purchased a new position in Eli Lilly and during the 4th quarter valued at about $103,000. Avestar Capital LLC purchased a new position in Eli Lilly and during the 4th quarter valued at about $100,000. MPS Loria Financial Planners LLC purchased a new position in Eli Lilly and during the 2nd quarter valued at about $128,000. San Francisco Sentry Investment Group CA purchased a new position in Eli Lilly and during the 2nd quarter valued at about $129,000. Finally, Willingdon Wealth Management purchased a new position in Eli Lilly and during the 3rd quarter valued at about $138,000. Hedge funds and other institutional investors own 77.63% of the company’s stock.
In other Eli Lilly and news, SVP Jeffrey N. Simmons sold 9,625 shares of the company’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $81.12, for a total transaction of $780,780.00. Following the completion of the sale, the senior vice president now owns 152,120 shares of the company’s stock, valued at $12,339,974.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Joshua L. Smiley sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, March 16th. The stock was sold at an average price of $79.20, for a total value of $237,600.00. Following the sale, the chief financial officer now directly owns 20,029 shares of the company’s stock, valued at approximately $1,586,296.80. The disclosure for this sale can be found here. Insiders have sold 15,261 shares of company stock valued at $1,225,085 in the last ninety days. Company insiders own 0.11% of the company’s stock.
Several research firms have weighed in on LLY. BMO Capital Markets reaffirmed a “sell” rating and set a $74.00 target price on shares of Eli Lilly and in a research note on Wednesday. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $85.00 target price on the stock in a research note on Tuesday. Jefferies Group reaffirmed a “buy” rating and set a $91.00 target price on shares of Eli Lilly and in a research note on Friday, March 23rd. TheStreet cut Eli Lilly and from a “b” rating to a “c” rating in a research note on Monday, March 5th. Finally, JPMorgan Chase set a $105.00 price target on Eli Lilly and and gave the company a “buy” rating in a research note on Monday, February 26th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have assigned a buy rating to the company’s stock. Eli Lilly and currently has a consensus rating of “Hold” and an average price target of $92.84.
Shares of Eli Lilly and stock opened at $76.85 on Friday. The company has a market cap of $86,113.99, a price-to-earnings ratio of 17.96, a P/E/G ratio of 1.43 and a beta of 0.26. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.32 and a quick ratio of 1.01. Eli Lilly and Co has a 12-month low of $73.69 and a 12-month high of $89.09.
Eli Lilly and (NYSE:LLY) last announced its earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.08 by $0.06. The firm had revenue of $6.16 billion during the quarter, compared to analysts’ expectations of $5.93 billion. Eli Lilly and had a positive return on equity of 33.01% and a negative net margin of 0.89%. The company’s revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.95 earnings per share. equities analysts predict that Eli Lilly and Co will post 4.87 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Eli Lilly and Co (NYSE:LLY) Shares Bought by Zeke Capital Advisors LLC” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/07/eli-lilly-and-co-lly-shares-bought-by-zeke-capital-advisors-llc.html.
Eli Lilly and Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.